LL-37
Untested in people for infections, mold illness or Lyme disease.
A natural defense peptide made by skin and white blood cells. It kills microbes in a dish and steers inflammation. Its one sizable human trial, a gel for leg ulcers, failed. A , also called Cathelicidin and CAP-18 fragment.
What the evidence shows
Side effects and risks
Who should avoid it: Injected use. Men trying to conceive should be especially cautious.
How it works
- Where it acts
- It punches holes in microbe membranes and signals to immune cells.
- What it changes
- It kills microbes in a dish, and can calm or fuel inflammation depending on the setting.
- What people notice
- A gel for leg ulcers failed in a trial. High levels are linked to inflammation in psoriasis and rosacea.
How it has been given in studies
Applied to the wound bed twice a week for 13 weeks. There is no established dose for injection.
Getting it in the United States
The legal route for LL-37
Not FDA-approved. FDA advisers have reviewed, or are due to review, whether pharmacies may compound it. Until FDA acts, there is no lawful route. Vials sold for research use are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacies
FDA removed cathelicidin LL-37 from Category 2 in 2026-04, but lawyers say it is still not eligible for compounding. It is one of five peptides set for advisory committee review before 2027-02.
Source: DLA Piper, 2026-07
Unreviewed injectable use
FDA's stated concerns are reproductive harm signals in animal work and possible tumour promotion. People using it outside trials take on those unknowns, plus impurity risk if the ingredient is research grade.
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Used in mold and Lyme communities
Reported problems
- Flu-like reactions
- Painful injections
Based on very few reports.
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Mixed resulttrial result in rare group - 2020
The company's later subgroup analysis reported complete healing in about 29 percent of large ulcers on the lower LL-37 strength against 8 percent on placebo. It admitted the subgroup analysis was not in the original statistical plan.
What experts and influencers say
Paraphrased from the linked sources.
Reports that animal and lab findings suggest harm to male reproduction and possible tumour promotion in some tissues. Says it lacks the data to know whether LL-37 would harm people.
US Food and Drug AdministrationSourceWarns against
Their review proposes LL-37 and its mimics as possible anticancer drugs for colon and gastric cancer. It also records that LL-37 is overproduced in breast, ovarian, lung and prostate tumours and can act as a growth factor.
Source: Frontiers in Oncology, 2015
Announced phase 2b results as positive, citing better healing of large venous leg ulcers. The same release reported no significant difference across the whole trial population.
Jonas Ekblom and Margit MahlapuuSourceRecommends
Money: Executives of the company developing LL-37 as ropocamptide
Concludes the effect depends on tissue. LL-37 promoted ovarian, lung, breast and prostate cancer in studies and suppressed colon, gastric and some blood cancers. Mechanisms remain unclear.
Source: Springer journal review, 2015
Archivum Immunologiae et Therapiae Experimentalis reviewSourceMixed view
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA
FDA flags LL-37 immunogenicity concerns and nonclinical signals of possible harm to male reproduction and tumor promotion in some tissues.
Regulator warning citing animal and lab signals
Cause Of Skin Condition Rosacea Discovered
University of California, San Diego
UC San Diego research linking excess cathelicidin and its processed peptides to rosacea inflammation, showing these peptides can drive disease.
Shows cathelicidin peptides can cause inflammation, not only fight germs
When options run out
Uses people turn to when standard treatment has failed.
Hard-to-heal venous leg ulcers
- Who
- Adults whose leg ulcers stay open despite standard wound care, treated with LL-37 applied to the wound in trials.
- Evidence
- One phase 2b trial (148 treated, 144 in the main analysis) missed its main endpoint: 13 patients in each of the three arms reached confirmed complete closure. No serious drug-related events were reported.
- Route
- Company trials in Poland and Sweden
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does LL-37 work for Lyme disease or mold illness?
Injections for infections, mold illness or Lyme disease have not been tested in people. The evidence comes from lab studies only.
Has LL-37 been tested in humans?
Its one sizable human trial, a gel for hard-to-heal leg ulcers in 148 patients, failed: ulcers closed in about 25% of people on either dose and 25% on placebo.
Is LL-37 safe?
FDA cites lab and animal findings of harm to male fertility and of tumor promotion in some tissues, plus the risk of immune reactions to injected peptide. Men trying to conceive should be especially cautious.
Can LL-37 be compounded in the US?
FDA advisers are due to review it for compounding by February 2027.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- EU Clinical Trials Register: LL-37 in venous leg ulcers, results
- FDA: bulk substances that may present significant safety risks
Structure: PubChem